Dr. Andrea Fan joined Kezar upon its founding in 2015 and currently serves as our Vice President, Biology and Head of Translational Research. She is an accomplished R&D leader, who brings over 20 years of experience in both small molecules and biologics drug development in immunology and oncology. Her career spans across discovery, pre-clinical, translational research, and clinical development. Most recently, she served as Head of Biology at Fluxion Bio, where she oversaw its oncology translational research programs. Previously, she led the biology/pharmacology group at Maxygen/Perseid Therapeutics and brought multiple next-generation protein therapeutics into autoimmunity and inflammation clinical trials in alliance with Astellas Pharma leading to corporate acquisition. Prior to that, she held senior research positions at diaDexus (a SB/Incyte joint venture) in novel genomic-based cancer target discovery and antibody drug development, and at GSK/Affymax in peptide mimetic and combinatorial chemistry drug discovery. She started her biopharmaceutical career at ChemoCentryx, an immunology therapeutics company founded by her post-doc advisor from DNAX Research Institute/Schering-Plough. She has made significant contributions to the discovery and early development of multiple now-approved products: PLAC®, OMONTYS® (Peginesatide), Nplate® (Romiplostim) and TAVNEOS® (Avacopan). Dr. Fan received her Ph.D. in Microbiology, Immunology, and Cancer Biology from the University of Virginia School of Medicine and Beirne B. Carter Center for Immunology Research.